Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Compliant and satisfactory completion of Enobia-sponsored clinical trial ENB-006-09~* Written informed consent by parent or other legal guardian prior to any study procedures being performed~* Parent or other legal guardian willing to comply with study requirements~Exclusion Criteria:~* Clinically significant disease that precludes study participation, in the Investigator's opinion~* Treatment with an investigational drug other than asfotase alfa~* Enrollment in any study (other than ENB-006-09) involving an investigational drug, device, or treatment for HPP~* Prior treatment with bisphosphonates

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- asfotase alfa (Type: EXPERIMENTAL): asfotase alfa starting dose 3 mg/kg/week SC injection, increased to 6 mg/kg/week SC injection

Based on this trial design, predict the completion outcome and termination type (if applicable).